RxDoctor Payments Data

Jodi Luchs, MD

Ophthalmology · West Palm Beach, FLNPI 1366413023

Payments from drug & device makers

$216,432in general payments, 2019–2025

Across 477 payments — averaging $453.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eyevance Pharmaceuticals LLC$71K
  • Bausch & Lomb Americas Inc.$50K
  • Sun Pharmaceutical Industries Inc.$44K
  • AbbVie$23K
  • Thea Pharma Inc.$10K
  • Osmotica Pharmaceutical Corp.$5K
  • plus $13K from 30 others

What the payments were for

  • Consulting fees$84,01941%
  • Speaking & faculty fees$91,93844%
  • Travel & lodging$12,1086%
  • Food & beverage$18,5609%
  • Education$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$216,432 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$318,258
Medicare patients
645
Services billed
2,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine177$125,868
LumiganBimatoprost166$57,727
CombiganBrimonidine Tartrate/Timolol118$33,683
ProlensaBromfenac Sodium76$24,620
XiidraLifitegrast22$20,773
Prednisolone Acetate457$16,179
CequaCyclosporine20$11,191
MieboPerfluorohexyloctane/Pf11$8,049
Latanoprost735$6,954
MoxifloxacinMoxifloxacin Hcl352$5,468
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol43$5,369
Cyclosporine18$4,493
RhopressaNetarsudil Mesylate13$3,898
Timolol Maleate357$3,305
Travoprost14$2,712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$23,290$217,278461 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$50,264$28,82233 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$217$24,62076 claims
Sun Pharmaceutical Industries Inc.Cequa$43,964$11,19120 claims
Aerie Pharmaceuticals, Inc.Rhopressa$133$3,89813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →